Hood River Capital Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,294 shares of the biopharmaceutical company’s stock after purchasing an additional 1,998 shares during the period. Hood River Capital Management LLC owned about 0.27% of Ultragenyx Pharmaceutical worth $6,087,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Sei Investments Co. bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $125,000. Tocqueville Asset Management L.P. raised its stake in shares of Ultragenyx Pharmaceutical by 8.0% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares during the period. Pacer Advisors Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 12.0% during the 2nd quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 365 shares during the period. Kazazian Asset Management LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $213,000. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 7.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares during the period. Institutional investors own 95.97% of the company’s stock.

A number of equities research analysts have recently commented on the company. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Sanford C. Bernstein assumed coverage on Ultragenyx Pharmaceutical in a research note on Thursday, July 27th. They set a “market perform” rating and a $72.00 target price on the stock. Canaccord Genuity set a $98.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, July 28th. HC Wainwright reiterated a “neutral” rating and set a $75.00 target price (up from $72.00) on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 8th. Finally, Evercore ISI assumed coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $63.00 price objective on the stock. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. Ultragenyx Pharmaceutical currently has a consensus rating of “Hold” and a consensus target price of $71.60.

In related news, CEO Emil D. Kakkis purchased 7,500 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were purchased at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the transaction, the chief executive officer now directly owns 430,569 shares in the company, valued at approximately $22,613,483.88. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 9.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/17/ultragenyx-pharmaceutical-inc-rare-stake-raised-by-hood-river-capital-management-llc.html.

Shares of Ultragenyx Pharmaceutical Inc. (RARE) traded up $0.90 on Friday, hitting $48.22. The stock had a trading volume of 495,500 shares, compared to its average volume of 433,728. Ultragenyx Pharmaceutical Inc. has a 12-month low of $44.02 and a 12-month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.87). The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. During the same quarter in the prior year, the company earned ($1.64) earnings per share. The company’s quarterly revenue was up 81.8% on a year-over-year basis. sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.24 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.